U.S. Stock Futures Hold Steady Ahead of Key Fed Decision 
Silver Prices Surge to New Record Above $60 as Supply Concerns and Fed Expectations Boost Demand 
Canada Stocks Steady as Markets Await Fed and BoC Decisions 
Holiday Economic Questions: What Bank of America Says You Should Expect 
Global Forex Markets Brace for Fed Decision as Yen Extends Weakness 
U.S. Open to Special Trade Terms for South Africa Under Possible AGOA Extension 
Japan’s Q3 Economic Contraction Deepens as Revised Data Signals Stronger Headwinds 
Asian Currencies Hold Steady as Traders Await Fed Decision; Aussie Dollar Edges Higher 
Australia’s Business Conditions Ease in November as Capacity Constraints Persist 
Stocks Slip as Investors Brace for Fed Decision and JPMorgan Warning Weighs on Markets 
ECB Signals Steady Rates Ahead as Policymakers Warn of Inflation Risks 
U.S. Defense Bill Sets Record $901 Billion Budget, Includes Ukraine Aid 
Global Markets Steady as Yen Holds Firm After Japan Earthquake Amid Central Bank Focus 
Oil Prices Hold Near Two-Week Highs as Markets Await Fed Rate Cut and Monitor Geopolitical Risks 
Global Currencies Steady Ahead of Key Central Bank Decisions 
UK Job Market Shows Persistent Weakness Ahead of November Budget 
RBA Holds Rates but Warns of Rising Inflation Pressures 
Global pharmaceutical stocks dropped sharply Monday after former U.S. President Donald Trump pledged to cut prescription drug prices by up to 59% to align with prices in other wealthy countries. The announcement came via a Truth Social post, following a similar promise made just a day earlier, citing a potential 30% to 80% reduction “almost immediately.”
Major U.S. drugmakers including AbbVie, Amgen, Pfizer, Eli Lilly, and Merck fell between 2.2% and 3.7% in premarket trading. Biotech shares also declined amid fears of heightened regulatory scrutiny and pricing pressure. Jefferies analyst Michael Yee noted the sector could see increased volatility due to policy uncertainty.
Trump’s proposal aims to address the high cost of medications in the U.S., which often pays nearly triple the price compared to other developed nations. However, details on how the proposed cuts will be implemented remain unclear. Leerink Partners analyst David Risinger emphasized the need for clarity on the timeline and affected government programs.
European pharmaceutical stocks also took a hit, with a healthcare index dropping 2.9%. AstraZeneca, GSK, and Roche declined between 3.3% and 6.8%. Analysts warn the move could influence EU-U.S. trade negotiations, potentially substituting tariffs with pharmaceutical price caps.
India’s Biocon and Lupin slid as the U.S. remains their largest export market. In Australia, CSL Ltd and Mayne Pharma fell as healthcare stocks dropped to a multi-week low. Japan’s pharma sector plummeted 6.5%, with Daiichi Sankyo losing over 8%, marking it the worst-performing sector on the Tokyo Exchange. In Hong Kong, Alphamab Oncology tumbled 14.4%.
The global sell-off comes as the U.S. and China agree to ease mutual tariffs, signaling potential shifts in trade dynamics and global market sentiment.
